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A Multi-Step NMR Screen for the Identification and Evaluation of 
Chemical Leads for Drug Discovery
Kelly A. Mercier, Matthew D. Shortridge, and Robert Powers*
Department of Chemistry, University of Nebraska-Lincoln, Lincoln, NE 68588
Abstract
A multi-step NMR based screening assay is described for identifying and evaluating chemical 
leads for their ability to bind a target protein. The multi-step NMR assay provides structure-related 
information while being an integral part of a structure based drug discovery and design program. 
The fundamental principle of the multi-step NMR assay is to combine distinct 1D and 2D NMR 
techniques, in such a manner, that the inherent strengths and weakness associated with each 
technique is complementary to each other in the screen. By taking advantage of the combined 
strengths of 1D and 2D NMR experiments, it is possible to minimize protein requirements and 
experiment time and differentiate between non-specific and stoichiometric binders while being 
able to verify ligand binding, determine a semi-quantitative dissociation constant, identify the 
ligand binding site and rapidly determine a protein-ligand co-structure. Furthermore, the quality 
and physical behavior of the ligand is readily evaluated to determine its appropriateness as a 
chemical lead. The utility of the multi-step NMR assay is demonstrated with the use of PrgI from 
Salmonella typhimurium and human serum albumin (HSA) as target proteins.
Keywords
Multi-Step NMR Screen; Protein-Ligand Binding; line broadening; saturation transfer difference; 
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INTRODUCTION
NMR has been demonstrated to be a useful addition to standard high-throughput screening 
(HTS) techniques to analyze small molecules for their ability to bind protein targets of 
interest.1,2 A typical HTS assay may yield a biological response upon addition of the 
inhibitor, but as a result of the complexity of the screening protocol and the mechanism of 
monitoring a response, it is generally not feasible to infer a binding interaction between the 
ligand and the protein of interest.3 There are numerous undesirable mechanisms resulting 
from poor physical behavior of the compound that will result in a positive response in an 
HTS screen (Fig. (1)).4–7 As a result, only a small percentage of the compounds identified 
by HTS may actually bind the protein target in a biologically relevant manner, where the 
remainder are false leads.8
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NMR ligand affinity screens are routinely used to validate these HTS hits by providing 
direct evidence for a binding interaction between the ligand and protein target through a 
variety of NMR methodologies.9–14 Observation of a binding event may occur through: 
changes in line-width and/or peak intensity (T1 and T2 relaxation changes);15–18 changes in 
the measured diffusion coefficient for the ligand;19,20 chemical shift perturbations for either 
the ligand21,22 or protein;10,23,24 induced transferred NOEs (trNOE) for the ligand;25–27 a 
saturation transfer difference (STD) between either the protein or bulk solvent to the ligand;
28–30
 appearance of new NOEs and/or intermolecular NOEs between the ligand and protein.
31–33
 The information obtained from the NMR analysis can be used to identify the binding 
site, measure a dissociation constant34 and determine a co-structure of the protein with the 
ligand.25,35,36 NMR screens also provide critical information on the viability of a compound 
to be classified as a “good” lead candidate by verifying the ligand’s structure, purity and 
solubility.37,38
NMR ligand affinity assays are also being routinely used to identify novel chemical leads by 
screening small fragment-based chemical libraries.39 SHAPES40 and other related 
libraries41,42 typically contain a small collection of low molecular-weight compounds (150–
250 Da) that correspond to fragments of known drugs or are diverse functional 
pharmacophores. The ultimate goal is to identify two or more ligands that can be chemically 
linked into a single inhibitor with a multiplicative improvement in relative binding affinities.
43
 Thus, this approach enables an extensive search of chemical space even though only 
<1000 compounds are experimentally screened by NMR.44
The NMR-based assays that are used to validate HTS hits and screen fragment-based 
libraries employ either ligand-detected NMR experiments45 or protein-detected NMR 
experiments.46 These fundamentally distinct NMR methods have different strengths and 
weaknesses related to the availability of protein material, the need for isotopically-labeled 
protein samples, the experiment time, the ability to differentiate between non-specific and 
stoichiometric binders and the ability to identify the ligand binding site. Ligand detected 
NMR screens utilize 1D NMR techniques, particularly relaxation measurements, diffusion-
edited measurements, saturation transfer differences, NOE pumping, and transferred NOEs 
to identify complex formation from changes in the ligand’s NMR spectrum.33,47–49 These 
1D NMR experiments eliminate the need for isotopically labeled protein samples while 
simultaneously minimizing protein sample requirements (nM-μM), decreasing data 
acquisition times (< 10 minutes) and increasing throughput. Unfortunately, these 1D NMR 
experiments do not provide information on the location of the ligand binding site and may 
not be able to differentiate between non-specific and stoichiometric binders. Thus, these 
methods are simply used to identify a binding interaction between the protein and ligand and 
are generally combined with modeling techniques, x-ray crystallography and other bioassays 
and biophysical techniques to optimize the chemical leads.50
Protein-detected NMR screens evaluate a small molecule’s ability to bind a protein from 
observed chemical shift perturbations (CSPs) in 2D 1H-15N HSQC43,51,52 or 2D 1H-13C 
HSQC protein NMR spectra.53 The observed CSPs also allow for the identification of the 
ligand binding site on the protein surface. Given, the use of 2D HSQC NMR spectra as a 
screen has some significant obstacles that limit its use in a high-throughput format. Mainly, 
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the relatively low sensitivity of NMR requires significant quantities of isotope enriched 
protein54 (> 3mg/mL) and data acquisition time (>10 minutes) per sample. This drastically 
impacts the number of compounds that can be realistically screened.55 NMR cryoprobes and 
flow-through probes provide partial solutions to these issues through either a 3–4 fold 
increase in sensitivity or a method for increased throughput, respectively.48,56 Nevertheless, 
given the high resource requirement for protein-detected NMR screens and the routine 
reliance on x-ray crystallography to generate protein-ligand co-structures,57 ligand-detected 
NMR screens are generally the method of choice. This is especially true given the expanding 
impact of fragment-based screening on the drug discovery process.39
This common practice of using only ligand-detected or protein-detected experiments 
significantly limits the beneficial impact of NMR-based screens and ignores the natural 
synergy of the various NMR methods. Also, the routine combination of NMR-based screens 
with other bioassays and biophysical techniques unnecessarily complicates and delays the 
process of validating biologically relevant chemical leads. To circumvent these limitations, a 
multi-step NMR screen has been devised that combines a number of NMR techniques to 
accomplish the necessary goals of identifying chemical leads, measuring a dissociation 
constant (KD) and determining a rapid protein-ligand co-structure in a single integrated 
protocol. To illustrate the utility of this method, screening results for PrgI from Salmonella 
typhimurium and human serum albumin (HSA) will be discussed.
MATERIALS AND METHODS
Functional Compound Library:
Our screening library is composed of 414 compounds with known biological activity in a 
total of 113 mixtures comprising 3–4 compounds.58 The design of our screening library 
guarantees “drug-like” characteristics, while increasing the overall activity of the library. 
Overall hit rates of >4.5% have been observed compared to 0.1–0.5% hit rates for random 
libraries.59 Reference NMR spectra are collected for both the individual compounds and the 
mixtures. These spectra provide NMR assignments for the compounds, while verifying 
compound solubility, compatibility, and the presence of distinct NMR resonances attributed 
to each compound in the mixture to avoid deconvolution.60 Identical chemical shifts, 
coupling patterns and line-widths between the mixture and individual NMR spectra verify 
that no interaction is occurring between the compounds and that the compounds are equally 
soluble and stable in the mixture. All the compounds have been individually weighed, 
dissolved to a concentration of 20 mM in D2O or D6-DMSO (Sigma-Aldrich, St. Louis, 
MO), and stored in standard 2 ml 96-well plates at −80oC.
Proteins:
Two proteins were used for analysis of the multi-step NMR method. Human serum albumin 
(96% essentially fatty acid free, Sigma-Aldrich, St. Louis, MO) is an important secondary 
target for efficacy screening and a well-established system for monitoring protein-ligand 
interactions.61 HSA was used as a model system for saturation transfer difference (STD) and 
line broadening experiments. Salmonella typhimurium protein PrgI (generously provided by 
Dr. Roberto De Guzman from the University of Kansas) is an example of a protein with a 
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well-defined function that was screened in our multi-step NMR assay as a starting point for 
drug discovery. This needle complex protrudes from the cell membrane of S. typhimurium to 
sense potential hosts. A solution structure for PrgI has recently been solved by NMR62 and 
the protein exhibits a helix-turn-helix motif.
Sample Preparation:
In general, 1D 1H NMR samples were screened in 20 mM deuterated bis-Tris (Cambridge 
Isotope, Andover, MA) at pH 7.0 (uncorrected), with 5% (v/v) dimethyl sulfoxide-d6 
(DMSO-d6) (Sigma-Aldrich, St. Louis, MO) and 11 μM 3-(trimethylsilyl)propionic-2,2,3,3-
d4 acid sodium salt (TMSP) (Cambridge Isotope, Andover, MA) screening buffer prepared 
in 99.98% deuterium oxide (Cambridge Isotope, Andover, MA). The 2D 1H-15N HSQC 
samples were prepared in a 20 mM deuterated bis-Tris screening buffer prepared in H2O at 
pH 7.0 and spiked with 5% deuterium oxide to obtain a lock signal. The protein (PrgI) and 
compound concentrations for each of the NMR experiments was 25 μM and 100 μM, 
respectively. For the HSA competition experiments the HSA concentration was increased 
from 2 μM to 20 μM.
For the non-competitive mixture screens, small molecule ligand samples were prepared in a 
10 mL stock solution that contained 20 µM of each ligand (ibuprofen, cinoxacin, L-proline, 
and adenosine 5’-triphosphate disodium salt), 1% (v/v) DMSO-d6, 10 µM TMSP and a 50 
mM potassium phosphate buffer at pH 7.0 (uncorrected) prepared in D2O.
Data collection:
All NMR spectra were collected at 298 K on a Bruker 500 MHz Avance spectrometer 
(Bruker Instruments, Billerica, MA) equipped with a triple-resonance, Z-axis gradient 
cryoprobe using a BACS-120 sample changer and IconNMR software for automated data 
collection.
The STD NMR spectra were collected using 512 transients, a sweep-width of 8992.8 Hz, 
and 16 K data points. A total time of 10 minutes was required to collect a single spectrum. 
The 1D line broadening NMR spectra for the non-competitive mixture titration experiments 
were collected using 512 transients, a sweep-width of 5482.6 Hz, 16 K data points, a 
relaxation delay of 2.0 s and the residual HDO resonance signal was suppressed using a 
composite pulse, solvent pre-saturation routine. A total time of 33 minutes was required to 
collect a single 1D spectrum including sample changing. The same NMR experimental 
parameters was used for screening the entire functional chemical library except 64 transients 
were collected per spectrum to reduce the total experiment time to 4.4 min per sample, 
including sample changing. The total 1D NMR acquisition time required to screen the entire 
functional chemical library was approximately 8 hrs. The 2D 1H-15N HSQC spectrum was 
collected with 16 transients, a sweep-width of 4734.85 Hz and 2 K data points in the direct 
dimension. The indirect dimension had a sweep-width of 1419.05 Hz with 256 data points. 
The total acquisition time for the secondary PrgI 2D 1H-15N HSQC screen of 6 samples was 
approximately 7.5 hrs.
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Protein Ligand Co-structures
Rapid determination of a ligand bound protein co-structure with PrgI was completed using 
the molecular docking program AutoDock 4.063 and the previously elucidated protein 
structure for PrgI.62 AutoDock 4.0 was used to generate 100 docked, ligand bound co-
structures, using the Lamarckian search algorithm, a population size of 300 with 500,000 
energy evaluations. The chemical shift difference map from the 2D 1H-15N HSQC data was 
used to guide the ligand docking in AutoDock and our in house AutoDock Filtering program 
(ADF) was used to select the best co-structure consistent with the experimental chemical 
shift perturbations.64 On average, a protein-ligand co-structure is calculated in ~30–45 
minutes on an Intel Xeon 3.06 GHz dual processor Linux workstation.
DISCUSSION
Description of the Multi-Step NMR Screen
The overall protocol for the multi-step NMR screen is illustrated in Fig. (2). There are four 
major components to the process: (i) verify good physical properties for the compounds 
being screened, (ii) identify ligands that bind the protein target, (iii) determine a binding 
affinity to prioritize the chemical leads and (iv) determine protein-ligand co-structures. The 
tiered approached used in the multi-step NMR screen minimizes valuable resources, such as 
protein samples and NMR instrument time, while increasing throughput. The first ligand-
detected NMR screening step is fast and minimizes sample requirements while simply 
identifying the compounds that bind the protein target. The second relatively resource 
intense protein-detected NMR screening step is only conducted on the positive hits from the 
first broad screen. In effect, the ligand-detected NMR screening step efficiently filters the 
screening library to identify binders for future evaluation. Similarly, the protein-detected 
NMR screening step filters out non-specific binders, confirms a stoichiometric interaction 
and identifies the ligand binding site. These experimental NMR spectra are then directly 
used to rapidly determine a protein-ligand co-structure, to measure a dissociation constant 
and to verify potential chemical leads. The direct outcome of these results from the multi-
step NMR screen, which are essential for a drug discovery process, is a unique aspect of the 
protocol.
Design of Chemical Library: There are numerous and equally acceptable approaches to 
designing a chemical library utilized in the multi-step NMR screen. The variety of possible 
compound library designs has been described at length in the scientific community.65–69 In 
general, the source of the chemical library will originate from the results of a standard 
biological assay as part of a high-throughput screen70 or from a fragment-based chemical 
library.39,42 Future iterations of the screen may utilize a focused or combinatorial library 
designed based on initial hits.71 The multi-step NMR screen is equally amenable to utilizing 
either single compounds and/or mixtures.60 It is preferable to design the compound 
mixtures58 to avoid a necessary de-convolution step to optimize the efficiency of the NMR 
screen.60
To illustrate the multi-step NMR screen, PrgI from Salmonella typhimurium and human 
serum albumin were screened against our functional chemical library.58 This library was 
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designed to contain compounds with “drug-like” characteristics based on the existence of 
known biological activity. Each compound in the library has a demonstrated binding affinity 
to a protein or protein class.
1D 1H NMR Spectra of Free Compound: A reference 1D 1H NMR spectra for each 
individual compound in the chemical library is collected in a standard aqueous buffer and 
maintained as part of a database. Fig. (3) shows the mixture of folic acid, 4-(2-aminoethyl) 
benzenesulfonyl fluoride hydrochloride, and erythro-9-(2-hydroxy-3-nonyl) adenine 
hydrochloride. The 1D 1H NMR spectrum for the free compound indicates the relative 
aqueous solubility and stability of the compound, the compound’s tendency to form high-
molecular weight aggregates or micelle-like structures and, in addition, it verifies the 
accuracy of the structure.6,7 Thus, the reference 1D 1H NMR spectra provides critical 
information to evaluate the utility of the compounds for screening in a drug discovery effort. 
The reference 1D 1H NMR spectra is also used to identify binding interactions based on 
spectral changes that are induced by the addition of the protein target.
1D STD and 1D line-broadening NMR Spectra of Protein:Compound 
Complex: The first goal of the multi-step NMR screen is to identify compounds that bind 
the protein target of interest while minimizing resources (protein and instrument time). The 
1D STD experiment72 is a likely choice since it is commonly used in NMR ligand affinity 
screens.73 The 1D STD experiment utilizes unlabeled protein samples with concentrations as 
small as 1 nM and NMR acquisition times on the order of minutes. Additionally, the 
screening step may be done as mixtures where the deconvolution of hits is accomplished by 
the comparison of the resulting 1D STD spectrum with the reference spectra of the free 
compounds.
The basic principal of the STD approach is to observe binding between the protein and the 
ligand by the transfer of saturation from the protein to the ligand. The ligand is in large 
excess (~20–30:1) relative to the protein. Saturation occurs by selectively irradiating a 
region of the NMR spectrum that contains only protein resonances, usually in the vicinity of 
0.0 ppm. In cases where no binding takes place, the resulting NMR spectrum for the 
compound is a null. If binding does occur between the protein and compound, then the 
resulting NMR spectrum would correspond to the spectrum of the free compound with 
potentially some protein background. Fig. (4) is an example of an STD experiment of a 
mixture of compounds, where only one compound exhibits binding to HSA. In the mixture 
of ibuprofen, cinoxacin, L-proline (Pro), and adenosine 5’-triphosphate disodium salt (ATP), 
only ibuprofen is a known HSA binder and is the only compound that exhibits a positive 
response in the STD experiment.
Despite the obvious appeal of the STD experiment, there are a number of serious drawbacks 
that significantly limit its value to the multi-step NMR screen. The method is overly 
sensitive to extremely weak (~mM) non-specific binders that result in a high percentage of 
false positives. Alternatively, tight binders (< 1 μM) are missed. The method is also not 
readily amenable to measuring a dissociation constant as part of the primary screen and 
requires significantly longer acquisition times relative to other 1D NMR experiments. An 
alternative approach to the 1D STD methodology is to measure a relaxation difference for 
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the compound in the presence of the protein.74 NMR line-widths are directly related to the 
intrinsic T2 relaxation of the molecule, which in turn is directly correlated with the MW of 
the molecule. Thus, the NMR line-width of a compound bound to a protein will significantly 
increase due to the dramatic increase in the apparent MW of the compound. As an 
illustration of 1D 1H NMR line-broadening experiments, a mixture of four compounds was 
screened against HSA. Again, the mixture contained ibuprofen, cinoxacin, L-proline (Pro), 
and adenosine 5’-triphosphate disodium salt (ATP). Fig. (5) shows a series of typical 1H 
NMR spectra for a range of HSA concentrations. The NMR peaks associated with ibuprofen 
are incrementally broadened by the addition of HSA. These results clearly demonstrate the 
application of 1D 1H NMR line-broadening to identify binders. It also verifies that the 
presence of non-binding compounds within a mixture does not interfere with observing a 
positive binding event. Another advantage of the 1D 1H NMR line-broadening experiment to 
the multi-step NMR screen is the ability to directly measure a dissociation constant from the 
assay.
Semi-Quantitative Dissociation Constants Directly from 1D Line-Broadening 
Screens: Typically, IC50 values obtained for each ligand from the HTS assay will provide 
an initial ranking of the chemical leads. A semi-quantitative dissociation constant (KD) can 
be obtained directly from the observed line-width changes in the multi-step NMR screen.34 
The change in NMR line-widths of the bound ligand (Ib) relative to the free ligand (If) can 
be plotted against the added protein concentration to generate a typical binding curve (Fig. 
(5b)). The data can be fit to our newly derived binding isotherm to calculate a KD:34
Bexpt = 1 −
IB
IF
= 1 − 1
1 +
c P T
L T + KD
where c =
vB
vF
− 1 (1)
[P]T and [L]T represent the total protein and ligand concentration, respectively, and the unit-
less NMR line width ratio constant (c) accounts for the proportional change in the free 
ligand line width (νF) upon binding of a ligand to a protein (νB). In the context of the multi-
step NMR screen, the binding isotherm can be simply rearranged to solve for the 
dissociation constant as a function of a single line-width change.
KD =
c P T
Bsingle
− c P T − L T (2)
The free ligand line width is directly measured from a reference spectrum with minimum 
processing and generally ranges between 1 and 2 Hz. The bound ligand line width is 
approximated by the molecular weight of the protein (MWp) using our derived linear 
equation.34
νP = 1 . 26 • MWP (3)
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For human serum albumin, the approximated bound ligand line width (νB) is 94.2 Hz. 
Ibuprofen was determined to bind HSA with a KD of 0.50 ± 0.1 μM (Fig. (5b)). The ability 
to directly measure a binding affinity as part of the 1D line-broadening step of the multi-step 
NMR screen enables a ranking and prioritization of these hits for further analysis in the 
assay.
1D Competition Experiment: Depending on the specifics of the protein target that is 
being screened, there may be value in determining if the hits from the previous binding 
analysis exhibit competitive binding to known substrates, ligands or other hits (Fig. (6)). 
This is easily accomplished by the addition of a known binder to the protein:compound 
mixture to determine if the increase in line-width previously observed is now lost or 
reduced. This would suggest that the binding of the compound and known ligand is mutually 
exclusive and suggestive of a similar or overlapping binding site on the protein.
Another important utilization of the 1D competition approach may be its application in the 
general multi-step NMR screening protocol to eliminate an unwanted class of compounds. 
Consider the situation where a known ligand exists for the protein target of interest, but it is 
undesirable to identify compounds that bind in a similar manner. By having the known 
ligand in molar excess relative to the compounds in the chemical library during the 1D line-
broadening NMR screening step, competitors to this known class of binders will be severely 
diminished. This will minimize wasted effort in follow-up experiments for undesirable 
compounds. Additionally, this same approach may be used to explore alternative binding 
sites on the protein with the end goal of chemically linking compounds that interact in the 
distinct binding sites or simply identifying an alternative interaction mode.
As an illustration of an NMR competition experiment, Fig. (6) shows a coumarin-analogue 
being displaced from HSA by following the changes in the ligands NMR line-width from the 
addition of warfarin. Both 7-hydroxy-4-methyl coumarin (KA = 2.1×104 M−1) and warfarin 
(KA = 2.5×105 M−1) bind selectively to Sudlow Site I on HSA.75 The NMR resonances of 
the coumarin-analogue broaden (Fig (6a, b)) from the addition of HSA, consistent with the 
known affinity of the compound to HSA. The addition of warfarin to the coumarin-HSA 
complex (Fig. (6c)) results in a sharpening of the coumarin NMR line-widths as the 
compound is displaced from HSA by warfarin. Furthermore, the binding of warfarin to HSA 
is evident by the line-broadening of the warfarin NMR resonances.
2D 1H-15N HSQC Spectra of Protein:Compound Complex: The next step in the 
multi-step NMR assay is the further evaluation of the hits from the 1D line-broadening 
NMR experiments. This is accomplished by collecting a 2D 1H-15N HSQC or 2D 1H-13C 
HSQC NMR experiment for the 13C or 15N –labeled protein target in the presence of each 
compound identified as a hit. For larger molecular-weight proteins (> 25 kDa) the TROSY 
version of the 2D 1H-15N HSQC experiment would be used.76 A complex is identified by 
the induced chemical shift perturbations in the protein spectrum caused by the addition of a 
ligand. Since the 2D HSQC NMR experiments are performed only on identified hits, greater 
care can be taken to maximize the quality of the NMR spectra and greater attention can be 
applied in the analysis of the data. This implies that a weak binding compound that may 
induce a minimal number of modest chemical shift perturbations has a less likelihood of 
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being missed and that false positives resulting from pH or buffer changes may be eliminated. 
Furthermore, greater care can be used to monitor changes in peak intensity and the 
appearance or disappearance of peaks in 2D HSQC spectra, which is also indicative of a 
binding event.
In conjunction with previously determined NMR assignments and structure determination of 
the protein target, it is a straightforward procedure to map the amino acid residues exhibiting 
chemical shift perturbations and/or intensity changes onto the protein’s molecular surface to 
define the binding site of an identified hit. An observed clustering of amino acid residues in 
the same region of the protein surface provides a level of confidence that the inhibitor is 
binding specifically to the protein. Conversely, a random distribution or a complete lack of 
amino acids that incur chemical shift or intensity change is strongly suggestive of a non-
specific binder.
Four compounds from the functional chemical library were identified as binders to PrgI 
using the 1D 1H line-broadening experiment (Fig. (7i)). The 2D 1H-15N HSQC spectra 
clearly shows that only one compound exhibits specific binding to PrgI based on the 
clustering of chemical shift perturbations on the PrgI surface (Fig. (7ii, iii)). These results 
demonstrate fundamental differences in the application of 1D line-broadening and 2D 
1H-15N HSQC spectra to differentiate between specific and non-specific binders. Essentially, 
the 2D HSQC NMR data is complimentary to and expands the information content 
obtainable from a 1D line-broadening screen. The 2D HSQC results confirm a specific 
binding interaction of the compound with the protein target while providing information on 
the binding site. Again, this illustrates the inherent strengths of the multi-step NMR screen. 
By integrating multiple NMR experiments, the strengths of one experiment compensates for 
the weakness of another.
Rapid Structure Determination and Iterative Design: After verifying that the 
compounds bind selectively to the protein, the structure of the protein-ligand complex is 
rapidly elucidated by NMR.64 The chemical shift perturbations (CSPs) obtained from the 2D 
1H-15N HSQC spectra are used to guide an AutoDock ligand docking calculation. The 
AutoDock 3D grid is reduced to a volume encompassing only the experimental binding site 
defined by the CSPs. Our AutoDock Filtering program (ADF) selects the best conformer(s) 
based on a consistency with the CSPs. Simply, the ligand is expected to be closer to residues 
that incurred larger chemical shift changes. On average, a protein-ligand co-structure is 
calculated within 35–45 minutes and exhibits an average RMSD of 1.17 ± 0.74 Å to high-
resolution NMR or x-ray structures.
Chemical shift perturbations observed in the 2D 1H-15N HSQC spectrum for PrgI bound to 
didecyldimethylammonium bromide identified a ligand binding site corresponding to 
residues at the bifurcation point of the two helices (Fig (7Aii)). This binding site 
corresponds to residues S6, L9, S13, K15, and D17 of helix 1 and N59, V65, K66, V67, 
F68, K69, D70, D72, A73 and L76 of helix 2 and was used to guide the AutoDock 
simulation. The best-conformer selected based on consistency with the magnitude of CSPs is 
shown in Fig (7Aiii), where didecyldimethylammonium adopts an extended conformation 
that straddles both helices of PrgI.
Mercier et al. Page 9
Comb Chem High Throughput Screen. Author manuscript; available in PMC 2019 July 10.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Another option of the multi-step NMR screen is to obtain 2D trNOE spectra of the 
protein:compound complex with the goal of determining the bound conformation of the 
ligand. This information can then be used in combination with the binding site identified 
from the 2D HSQC data to aid in the rapid determination of the co-structure. The accuracy 
of an AutoDock calculation is often dependent on the number of torsional degrees of 
freedom in the ligand.77,78 Therefore, knowledge of the bound ligand’s conformation would 
limit the number of torsional angles permitted to undergo free rotation during the AutoDock 
simulation. The utility of this step depends on the size and conformational flexibility of the 
compound and is typically unnecessary.
Finally, the multi-step NMR protocol is amenable to an iterative approach where a library of 
structural analogs, based on the initial hits, can be used to further optimize the affinity and 
activity of the ligand.
CONCLUSION
The multi-step NMR assay is used in combination with HTS screens to expedite the 
validation and prioritization of lead compounds. The multi-step NMR methodology supplies 
information that is critical to a drug design program that is absent in traditional HTS assays. 
The multi-step NMR screen provides direct evidence that the compound of interest binds to 
the desired protein target in a biologically relevant manner. Additionally, information on the 
stoichiometry of binding, the dissociation constant, the identification of the ligand-binding 
site and a protein:ligand co-structure are all readily obtainable from the assay. The multi-
step NMR easily provides information on the physical behavior of the ligand itself. The 
assay rapidly identifies such properties as relative solubility, purity and stability that are 
fundamental for a good lead compound. The strength of the multi-step NMR screen arises 
from the integration of ligand-detected and protein-detected NMR methodologies.
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Fig. (1). 
The reality of screening compound libraries. A number of undesirable mechanisms may lead 
to a positive response in an HTS assay that is not a result of a specific interaction of the 
compound with the protein target.
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Fig. (2). 
Flow diagram for the multi-step NMR screen.
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Fig. (3). 
An example of a reference 1H NMR spectrum for a compound mixture from the functional 
chemical library comprised of (A) folic acid, (B) AEBSF and (C) erythro-9-(2-hydroxy-3-
nonyl)adenine hydrochloride. The DMSO solvent peak, TMSP reference peak and each peak 
corresponding to a compound in the mixture are labeled.
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Fig. (4). 
An example of a STD NMR experiment with a mixture of ibuprofen, cinoxacin, L-proline 
(Pro), and adenosine 5’-triphosphate disodium salt (ATP). The only peaks from ibuprofen in 
the STD experiment (B) are associated with the compound that bound to 2 μM of HSA and 
can be identified from the reference mixture spectrum (A) collected before the protein was 
added.
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Fig. (5). 
(A) A titration mixture of ibuprofen, cinoxacin, L-proline (Pro), and adenosine 5’-
triphosphate disodium salt (ATP) with increasing concentrations (i) 0 μM, (ii) 0.4 μM, (iii) 
1.0 μM, and (iv) 3.0 μM of HSA. (B) Only ibuprofen binds HSA and the decrease in peak 
intensity describes the binding curve from eq 1. The resulting equilibrium dissociation 
constant (KD) for ibuprofen was 0.46 ± 0.8 μM with a NMR line width ratio constant (c) of 
31.8.
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Fig. (6). 
A competition experiment between two known binders to HSA. (A) 7-hydroxy-4-methyl 
coumarin alone, (B) 7-hydroxy-4-methyl coumarin in the presence of HSA, and (C) 7-
hydroxy-4-methyl coumarin in the presence of HSA and warfarin. The 7-hydroxy-4-methyl 
coumarin (KA =2.1×104 M−1) is displaced by the addition of warfarin (KA =2.5×105 M−1).
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Fig. (7). 
The 1D line broadening and 2D 1H-15N HSQC multi-step NMR protocol was used to 
identify five compounds that bound to the Type III Secretion System (TTSS) protein PrgI of 
S. typhimurium. (A) One of the five compounds, didecyldimethylammonium bromide, 
showed minimal changes in line broadening experiments (i) but significant chemical shift 
changes in the 2D HSQC secondary screen (ii). These chemical shift changes were mapped 
to the surface of PrgI and didecyldimethylammonium bromide was docked to the region 
using AutoDock combined with our in house ADF program (iii). (B) The strongest binding 
ligand from the 1D NMR screens (i) showed no chemical shift changes in the 2D NMR 
screen (ii). This suggests the compound binds non-specifically to PrgI and therefore no 
binding site was mapped to the protein’s surface (iii).
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